

Research Article

Exploring the Pharmacological Mechanism of the Herb Pair “HuangLian-GanJiang” against Colorectal Cancer Based on Network Pharmacology

Benjiao Gong ¹, Yanlei Kao ², Chenglin Zhang,¹ Huishan Zhao ¹, Fudong Sun ¹,
and Zhaohua Gong ¹

¹Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, Shandong Province, China

²Yantai Hospital of Traditional Chinese Medicine, Yantai 264000, Shandong Province, China

Correspondence should be addressed to Fudong Sun; 13225357727@163.com and Zhaohua Gong; gongzhaohuayt@163.com

Benjiao Gong and Yanlei Kao contributed equally to this work.

Received 18 July 2019; Revised 16 September 2019; Accepted 12 October 2019; Published 29 November 2019

Academic Editor: Juntra Karbwang

Copyright © 2019 Benjiao Gong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Since the herb pair Huang Lian-Gan Jiang (HL-GJ) was put forward as conventional compatibility for cold-heat regulation in the middle energizer in the theory of Traditional Chinese Medicine (TCM), their therapeutic effects were observed on the prevention and treatment of intestinal inflammation and tumors including colorectal cancer (CRC). However, the active compounds, crucial targets, and related pathways of HL-GJ against CRC remained unclear. The purpose of this research was to establish a comprehensive and systemic approach that could identify the active compounds, excavate crucial targets, and reveal anti-CRC mechanisms of HL-GJ against CRC based on network pharmacology. We used methods including chemical compound screening based on absorption, distribution, metabolism, and excretion (ADME), compound target prediction, CRC target collection, network construction and analysis, Gene Ontology (GO), and pathway analysis. In this study, eight main active compounds of HL-GJ were identified, including Gingerenone C, Isogingerenone B, 5,8-dihydroxy-2-(2-phenylethyl) Chromone, 2,3,4-trihydroxy-benzenepropanoic acid, 3,4-dihydroxyphenylethyl Alcohol Glucoside, 3-carboxy-4-hydroxy-phenoxy Glucoside, Moupinamide, and Obaculactone. HRAS, KRAS, PIK3CA, PDE5A, PPARG, TGFBR1, and TGFBR2 were identified as crucial targets of HL-GJ against CRC. There were mainly 500 biological processes and 70 molecular functions regulated during HL-GJ against CRC ($P < 0.001$). There were mainly 162 signaling pathways contributing to therapeutic effects ($P < 0.001$), the top 10 of which included DAP12 signaling, signaling by PDGF, signaling by EGFR, NGF signaling via TRKA from the plasma membrane, signaling by NGF, downstream signal transduction, DAP12 interactions, signaling by VEGF, signaling by FGFR3, and signaling by FGFR4. The study established a comprehensive and systematic paradigm to understand the pharmacological mechanisms of multiherb compatibility such as an herb pair, which might accelerate the development and modernization of TCM.

1. Introduction

Colorectal cancer (CRC) is the third major malignant tumor diagnosed globally and accounts for the fourth cancer mortality worldwide [1]. Furthermore, the incidence is still rising all over the world despite the major milestone in early diagnosis and treatment of CRC [2]. Clearly, it has become a powerful threat to public health due to high morbidity and mortality [3]. Although the pathogenesis of CRC is complex and still not fully illuminated, the interactions of risk factors

including the environmental, lifestyle, and genetic factors play outstanding roles in initiation and ignition of CRC [4, 5]. The therapeutic regimens for CRC include surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy [6–8]. The development of therapies for CRC still cannot cope with its high mortality owing to frequent recurrence and metastasis. Given this, it is in desperate need of more effective and less toxic treatment for CRC.

Traditional Chinese Medicine (TCM) has always played an important part in treating diseases for Asian people and is more

and more widely recognized in western countries [9]. TCM has formed its own unique culture with differences in substance, methodology, and philosophy from modern medicine [10]. Multiherb compatibility has been regarded as the essence of TCM theories [11]. Herb pairs are the simplest and the most fundamental form of multiherb therapy and Chinese herb formulae often contain special herb pairs, which are asserted to assemble and interpret single combinations of traditionally classified herbal properties, connecting mutual enhancement, assistance, restraint and suppression, or antagonism [12]. Better pharmacological efficacy of herb pairs is usually due to the synergy effects from ingredients with special pharmacokinetic profile [13].

In TCM herbs, Huang Lian (HL) is derived from dried roots of *Coptis chinensis* Franch., *Coptis teeta* Wall., and *Coptis deltoidea* C. Y. Cheng et Hsiao, which are, respectively, called “Wei Lian,” “Yun Lian,” and “Ya Lian,” according to China Pharmacopoeia. Under the guidance of TCM theory, HL could alleviate heat, astringe extra fluids, and resolve toxin in the body. Zingiberis rhizoma (“Gan Jiang” in Chinese, GJ) is the dried root of *Zingiber officinale* Rocs distributed in Southwest China. GJ has the effects of warming the spleen and stomach for dispelling cold and restoring venation in accordance with China Pharmacopoeia. HL and GJ seem to be cold and hot in terms of medicinal properties and are not synergistic with each other. Since the creation of the herb pair “HL-GJ” for treating diseases of the spleen-stomach system by the ancient Chinese book “Treatise on Febrile Diseases,” combination of frigotherapy and pyretotherapy has become a conventional compatibility of cold-heat regulation in the middle energizer. Recent studies have found that the compatibility of HL with GJ could not only make their medicinal properties milder but also have strong synergistic effects and could increase pharmaceutical efficiency and reduce toxicity compared with individual applications. HL is a common medicine used to treat gastrointestinal diseases in the field of TCM. Modern pharmacological studies have shown that HL could inhibit invasion and metastasis of colorectal cancer cells and has inhibitory and clinically therapeutic effects on colon cancer [14, 15]. But HL often causes constipation, anorexia, and a series of symptoms of cold of insufficiency type due to its bitter and cold medicinal properties. Based on the theoretical guidance of combination of frigotherapy and pyretotherapy, compatibility of appropriate dose of GJ can alleviate these side effects of HL clinically, so that HL can take effect in expelling pathogenic factors and restoring the balance of human body. Chinese researchers have also reported that GJ can inhibit the proliferation and promote apoptosis of tumor cells. Although some achievements have been made in the pharmacological research studies of HL, GJ, and their monomeric substances, the studies on the molecular biology of the herb pair “HL-GJ” are relatively deficient. Hence, this study is expected to provide a theoretical basis for herb compatibility and achieve a breakthrough in the treatment of CRC.

Network pharmacology has been brought into focus in recent years, which integrates pharmacodynamics, pharmacokinetics, and system-level network analysis and can reveal the

multifaceted mechanisms of herbal formulae treating complicated diseases from proteomics or at the systematic level [16–18]. Particularly, it has become a novel strategy to elucidate the interactive relationship between multicomponents and multitargets of TCM and a research hotspot to investigate multiple molecular mechanisms of multitarget compounds affecting biological networks for herbal medicines [19–21]. Therefore, we employed the network pharmacology to probe the pharmacological mechanisms of the herb pair “HL-GJ” against CRC in this study. Meanwhile, the relationships among herbs, compounds, and targets were also investigated. Finally, the multicomponent, multitarget, and multipathway mechanisms were illuminated for HL-GJ against CRC based on network analysis.

2. Materials and Methods

2.1. Chemical Compounds of HL-GJ. Chemical compounds were obtained from the Traditional Chinese Medicine Systems Pharmacology Database [22] (TCMSP, <http://ibts.hkbu.edu.hk/LSP/tcmsp.php>) and the Traditional Chinese Medicine Integrated Database [23] (TCMID, <http://www.megabionet.org/tcmid/>). Compounds were screened according to predicted oral bioavailability (OB) and drug-likeness (DL) values and reserved if $OB \geq 30\%$ and $DL \geq 0.18$, which was a recommended criterion by the TCMSP database. The constituent compounds of HL-GJ were summarized for further research after removing duplication.

2.2. Target Fishing for HL-GJ. Target fishing was executed to investigate potential targets of constituent compounds of HL-GJ. PharmMapper [24] (<http://lilab.ecust.edu.cn/pharmmapper/>), an online server using the pharmacophore mapping approach for potential drug target identification, was employed to predict the potential protein targets based on 3D molecular structure. The 3D molecular structure files (.SDF) were obtained from the PubChem [25] (<https://pubchem.ncbi.nlm.nih.gov/>), a public repository for providing information of chemical compounds and their biological activities. Compounds without precise structural information cannot be predicted targets and were removed. Eventually, predicted protein targets were harvested with normalized fit score >0.9 . The final target information was normalized via UniProt (<https://www.uniprot.org/>) [21].

2.3. CRC Targets. Different target information associated with CRC was collected from TTD (<https://db.idrblab.org/ttd/>) [26] and OMIM (<http://www.omim.org/>) [27] databases. CRC targets were retrieved after deleting duplicate data. Common targets of both CRC and the chemical compounds were considered potential targets.

2.4. Protein-Protein Interaction Data. The data of protein-protein interaction (PPI) were obtained from String [28] (<https://string-db.org>, ver 10.5), with species limited to “*Homo sapiens*” and the confidence score >0.9 . String is a




FIGURE 2: Compound-compound target network (blue triangles represented predicted protein targets with normalized fit score >0.9). Yellow octagon: chemical compound; blue triangle: chemical target.

3. Results and Discussion

3.1. Herb-Compound-Compound Target Network. As shown in Figure 1, the herb-compound network was composed of 67 nodes (2 herb nodes and 65 chemical compound nodes) and 65 edges. A total of 65 satisfactory chemical compounds were gained from the herb pair “HL-GJ,” including 24 in HL and 41 in GJ, which was consistent with the feature of multiple components of TCM (Tables S1 and S2). Among the 65 chemical compounds, one compound could not be successfully predicted targets and two compound targets did not confirm to the filter criterion. So, the compound-compound target network contained 169 nodes (62 chemical compound nodes and 107 target nodes) and 1189 edges as

shown in Figure 2 (Table S3). In this network, it was not hard to find that each compound corresponded to multiple targets. For instance, Berberine in HL modulated PPIA, CA2, TTR, BCHE, AR, CYP19A1, and ESR2. Gingerol in GJ modulated 25 targets including PPIA, CA2, CCNA2, GSTP1, BCHE, MAOB, and so on. Also, PPIA was regulated by a number of compounds from HL and GJ. These phenomena were consistent with the feature of multiple targets of TCM and the synergy effect of multiherb compatibility. Figure 3 integrated the herb-compound network and the compound-compound target network, which was convenient for observing the relationship among herb, compound and compound target, and the potential pharmacological effects of the herb pair “HL-GJ.” Overlong names of compounds




FIGURE 3: Herb-compound-compound target network integrated the relationship among herb, compound, and compound target, which might exert great influence during HL-GJ acting on CRC. Green arrow: herb; yellow octagon: chemical compound; blue triangle: chemical target.

were replaced with corresponding PubChem ID numbers in figures, which were summarized in Tables S1 and S2.

PharmMapper is widely employed for computational target detection and can offer top 300 potential targets for the query compound in default [31]. The predicted targets with a normalized fit score >0.9 were adopted in this study using PharmMapper. Several probable targets of active compounds from HL and GJ have been documented in other studies. Berberine can suppress AR signaling and present a promising mediator for the prevention or treatment of prostate cancer [32]. Chlorogenic acid may serve as a chemosensitizing mediator leading to tumor growth suppression due to its ability of activating or inhibiting some

important pathways such as the EGFR/PI3K/mTOR pathway [33]. Columbianadin induced apoptosis of colon cancer (HCT116) cells, which was connected with the modulation of caspase-3, caspase-9, Bim, Bcl-2, Bax, and Bid [34]. Obaculonone and obaculonone glucoside (OG) induced the apoptosis of colon cancer (SW480) cells through reducing ratio of bcl2/bax gene transcription, activating caspase-3, and inducing fragmentation of DNA [35]. Quercetin might be an attractive chemical scaffold, which could generate novel derivatives such as PIM1, possessing various kinds of antikinase activities [36]. In 10-gingerol-treated human colon cancer (HCT116) cells, there was an increased ratio of Bax/Bcl-2 with induction of apoptosis through the activation




FIGURE 4: Protein-protein interaction network represented the reaction of HL-GJ response to CRC in vivo. Red ellipse: common target between CRC and chemical compounds; purple ellipse: human protein directly or indirectly interacted with common target.

of caspase-9, caspase-3, and poly-ADP-ribose polymerase in a dose-dependent manner [37]. Active fractions including quercetin and β -sitosterol had an apoptotic effect on breast cancer (MCF-7 and MDA-MB-231) cells possibly through the mitochondrial pathway due to the activation of caspase3/7 [38]. The above description showed the precision of target prediction for PharmMapper.

3.2. PPI Network Analysis. One hundred and eighty-six CRC targets were collected from TTD and OMIM databases (Table S4). Targets between CRC and chemical compounds were mapped, and 6 common targets were found. Fifty-seven other human proteins directly or indirectly interacted with 6 common targets were achieved from String database.

The PPI network of the common targets is shown in Figure 4, including 63 nodes (6 common target nodes and 57 other human protein nodes), which might represent the reaction of HL-GJ response to CRC in vivo. NetworkAnalyzer was employed to calculate topological parameters such as Degree, Betweenness Centrality, and Closeness Centrality of the 63 targets in the PPI network (Table S5) in order to identify key nodes in the network. The corresponding median values of Degree, Betweenness Centrality, and Closeness Centrality were 7.02, 0.04, and 0.63. Thus, the nodes with “Degree >7.02,” “Betweenness Centrality >0.04,” and “Closeness Centrality >0.63” were considered as key targets of HL-GJ against CRC. As a result, HRAS, KRAS, PIK3CA, PDE5A, PPARG, TGFB1, and TGFB2 were identified as crucial targets of HL-GJ against CRC.




FIGURE 5: PPI network of herb-compound-compound target-CRC target-other human proteins traced the compounds acting on common targets and provided a straightforward reflection of the relationship from herb to compound to disease. Green arrow: herb; yellow octagon: chemical compound; red ellipse: common target between CRC and chemical compounds; purple ellipse: human protein directly or indirectly interacted with common target.

RAS family members of proteins often appeared in mutated and oncogenic forms in human tumors. Four diverse RAS proteins were encoded by 3 genes: *KRAS* (2 splice variants), *HRAS*, and *NRAS* [39]. RAS protein mutations could result in nonreversible reduction in GTPase activity or inability of activating GTPase [40], and mutations in *KRAS* held about 85% of overall RAS mutations in human tumors; *NRAS* about 15%; and *HRAS* less than 1% [41]. The probability of *KRAS* mutation was approximately 30–50% in CRC [42], associated with advanced disease status, greater ratio of right-sided colon tumors, poor tumor differentiation, and more liver metastasis [43–45]. *KRAS* was also reported to be associated with mucin component and lymphovascular invasion [46]. *KRAS* was known to be an alternative marker of anti-EGFR antibodies at present [47]. *HRAS* mutation could cause augmentation of phosphatidylinositol-3-kinase signaling [48] and also appeared in bladder and oropharyngeal cancer [49, 50]. Nevertheless, none of the mutations in the RAS gene family was a remarkable prognostic factor in CRC [46]. The PI3K protein encoded by *PIK3CA* was a lipid kinase that played a crucial role in promoting and regulating signal pathways relevant to cell proliferation, migration, apoptosis, and metabolism [51, 52]. *PIK3CA* mutation occurred 15–20% in colorectal cancer [53]. *PIK3CA* mutation contributed to the survival and proliferation of CRC stem cells, which induced chemotherapy resistance and poor prognosis [54], and reduced the hazard of peritoneal metastases [55]. PI3K upregulation was able to inhibit the apoptosis of CRC cells as well [56]. The expression level of PDE5A was upregulated after treatment with American ginseng and ginsenoside Rg3 in human CRC cells [57]. Significant association was found between PPARG variants and CRC [58]. PPARG might be the target of miR-34a and the potential therapeutic target of CRC [59]. Nonsteroidal anti-inflammatory drugs

suppressed CRC stem cells via inhibiting PTGS2 and NOTCH/HES1 and activating PPARG [60]. The rs1590 variant of TGFBR1 might possess a significant association with CRC risk, and the hypomorphic variant TGFBR1 * 6A affected migration and invasion in CRC cells [61, 62]. The miR-3191 promoted the migration and invasion by targeting TGFBR2 in CRC cells, and the miR-371~373/TGFBR2/ID1 signaling axis might regulate the self-renewal of tumor-initiating cells and metastatic colonization as a novel mechanism [63, 64]. In summary, literature review supported HRAS, KRAS, PIK3CA, PDE5A, PPARG, TGFBR1, and TGFBR2 as crucial targets of HL-GJ against CRC and confirmed the reliability of key target screening via calculating topological parameters.

3.3. PPI Network of Herb-Compound-Compound Target-CRC Target-Other Human Proteins. The network traced the compounds of HL-GJ acting on common targets between CRC and chemical compounds as shown in Figure 5, which covered 93 nodes (2 herb nodes, 28 compound nodes, 6 common target nodes, and 57 other human protein nodes) and 292 edges. The network provided a straightforward reflection of the relationship from herb to compound to disease. In order to identify more important compounds, the topological parameters of 28 compound nodes were calculated by NetworkAnalyzer (Table S6). The median values of Degree, Betweenness Centrality, and Closeness Centrality were 2.54, 0.03, and 0.21, respectively. Nodes with “Degree >2.54,” “Betweenness Centrality >0.03,” and “Closeness Centrality >0.21” were regarded as major compounds of HL-GJ against CRC. Compounds satisfying requirements contained Gingerenone C, Isogingerenone B, 5,8-dihydroxy-2-(2-phenylethyl) Chromone, 2,3,4-trihydroxy-benzenepropanoic acid, 3,4-dihydroxyphenylethyl Alcohol Glucoside,

essential survival signals in CRC, it might cause intrinsic resistance to Irinotecan, and the strong synergy was seen between the FGFR3 inhibitor and IRI [78]. The first specific inhibitor of FGFR4 was verified to restrain the proliferation of CRC cells, augment apoptosis rate, dispute cell cycle, and inhibit EMT, and might be a new targeted drug [79]. These results suggested that these main pathways might interact to produce the therapeutic efficacy of HL-GJ against CRC.

4. Conclusion

In this study, a systematical pharmacological approach was established to expound the active compounds, therapeutic targets, and pharmacological mechanisms of HL-GJ against CRC. Sixty-five constituent compounds of HL-GJ were summarized from TCMSP and TCMID, and their targets were predicted based on PharmMapper. One hundred and eighty-six CRC targets were collected from TTD and OMIM databases. Targets of CRC and chemical compounds were mapped to identify 6 common targets, and fifty-seven other human proteins directly or indirectly interacted with common targets were achieved from the String database. By network construction and topological parameter calculation, eight active compounds and seven crucial targets of HL-GJ against CRC were identified. Moreover, the biological processes, molecular functions and pathways regulated by HL-GJ treating CRC were systematically interpreted. This study provided a scientific and powerful mean to view the multiscale pharmacological mechanisms of HL-GJ against CRC from a systematical perspective.

Data Availability

The data used to support the findings of this study are included within the supplementary information files

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary Materials

Table S1: chemical compounds of HL-GJ from TCMSP. Table S2: chemical compounds of HL-GJ from TCMID. Table S3: compounds in HL-GJ and corresponding targets. Table S4: CRC targets. Table S5: topological parameters for PPI Network. Table S6: topological parameters for compound nodes. Table S7: Gene Ontology (BP) biological process analysis. Table S8: Gene Ontology (MF) molecular function analysis. Table S9: pathway analysis. (*Supplementary Materials*)




References

[1] M. Arnold, M. S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, "Global patterns and trends in colorectal cancer incidence and mortality," *Gut*, vol. 66, no. 4, pp. 683–691, 2017.

- [2] A. Jemal, F. Bray, M. M. Center et al., "Global cancer statistics," *CA: A Cancer Journal for Clinicians*, vol. 61, no. 2, pp. 69–90, 2015.
- [3] I. A. Issa and M. Nouredine, "Colorectal cancer screening: an updated review of the available options," *World Journal of Gastroenterology*, vol. 23, no. 28, pp. 5086–5096, 2017.
- [4] D. Colussi, G. Brandi, F. Bazzoli, and L. Ricciardiello, "Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention," *International Journal of Molecular Sciences*, vol. 14, no. 8, pp. 16365–16385, 2013.
- [5] C. Carvalho, A. Marinho, B. Leal et al., "Association between vitamin D receptor (VDR) gene polymorphisms and systemic lupus erythematosus in Portuguese patients," *Lupus*, vol. 24, no. 8, pp. 846–853, 2015.
- [6] C. Lucas, N. Barnich, and H. T. T. Nguyen, "Microbiota, inflammation and colorectal cancer," *International Journal of Molecular Sciences*, vol. 18, no. 6, p. 1310, 2017.
- [7] G. Wang, C.-C. Feng, S.-J. Chu et al., "Toosendanin inhibits growth and induces apoptosis in colorectal cancer cells through suppression of AKT/GSK-3 β / β -catenin pathway," *International Journal of Oncology*, vol. 47, no. 5, pp. 1767–1774, 2015.
- [8] L. Faugeras, A. Dili, A. Druetz, B. Krug, C. Decoster, and L. D'Hondt, "Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy," *Critical Reviews in Oncology/Hematology*, vol. 115, pp. 59–66, 2017.
- [9] T. Xue and R. Roy, "Studying traditional Chinese medicine," *Science*, vol. 300, no. 5620, pp. 740–741, 2003.
- [10] T. W. Corson and C. M. Crews, "Molecular understanding and modern application of traditional medicines: triumphs and trials," *Cell*, vol. 130, no. 5, pp. 769–774, 2007.
- [11] X.-J. Li and H.-Y. Zhang, "Synergy in natural medicines: implications for drug discovery," *Trends in Pharmacological Sciences*, vol. 29, no. 7, pp. 331–332, 2008.
- [12] H. Li, C. W. Yap, C. Y. Ung, Y. Xue, Z. W. Cao, and Y. Z. Chen, "Effect of selection of molecular descriptors on the prediction of blood–brain barrier penetrating and non-penetrating agents by statistical learning methods," *Journal of Chemical Information and Modeling*, vol. 45, no. 5, pp. 1376–1384, 2005.
- [13] X. H. Ma, C. J. Zheng, L. Y. Han et al., "Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives," *Drug Discovery Today*, vol. 14, no. 11–12, pp. 579–588, 2009.
- [14] X. Liu, Q. Ji, N. Ye et al., "Berberine inhibits invasion and metastasis of colorectal cancer cells via COX-2/PGE2 mediated JAK2/STAT3 signaling pathway," *PLoS One*, vol. 10, no. 5, Article ID e0123478, 2015.
- [15] L. Dong, H. Shi, G. Ji, and D. Wu, "Effects of *Coptis chinensis* and *Evodia rutaecarpa* water extract on DMH-induced pre-cancerous lesion of colon," *Zhongguo Zhong Yao Za Zhi*, vol. 35, no. 9, pp. 1185–1188, 2010.
- [16] S. Sheng, J. Wang, L. Wang et al., "Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong Capsule with experimental support using disseminated intravascular coagulation rats," *Journal of Ethnopharmacology*, vol. 154, no. 3, pp. 735–744, 2014.
- [17] X. Li, L. Wu, W. Liu et al., "A network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-compound, multi-target, multi-pathway mode of action," *PLoS One*, vol. 9, no. 5, Article ID e95004, 2014.
- [18] T. Xu, S. Li, Y. Sun et al., "Systematically characterize the absorbed effective substances of Wutou decoction and their

- metabolic pathways in rat plasma using UHPLC-Q-TOF-MS combined with a target network pharmacological analysis,” *Journal of Pharmaceutical and Biomedical Analysis*, vol. 141, pp. 95–107, 2017.
- [19] X. Li, X. Xu, J. Wang et al., “A system-level investigation into the mechanisms of Chinese traditional medicine: compound Danshen formula for cardiovascular disease treatment,” *PLoS One*, vol. 7, no. 9, Article ID e43918, 2012.
- [20] B. Y. Kim, K. H. Song, C. Y. Lim, and S. I. Cho, “Therapeutic properties of *Scutellaria baicalensis* in db/db mice evaluated using connectivity map and network pharmacology,” *Science Report*, vol. 7, no. 1, p. 41711, 2017.
- [21] U. Chandran and B. Patwardhan, “Network ethnopharmacological evaluation of the immunomodulatory activity of *Withania somnifera*,” *Journal of Ethnopharmacology*, vol. 197, pp. 250–256, 2017.
- [22] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” *Journal of Cheminformatics*, vol. 6, no. 1, p. 13, 2014.
- [23] R. Xue, Z. Fang, M. Zhang, Z. Yi, C. Wen, and T. Shi, “TCMID: traditional Chinese Medicine integrative database for herb molecular mechanism analysis,” *Nucleic Acids Research*, vol. 41, no. D1, pp. D1089–D1095, 2012.
- [24] X. Wang, Y. Shen, S. Wang et al., “PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database,” *Nucleic Acids Research*, vol. 45, no. W1, pp. W356–W360, 2017.
- [25] S. Kim, P. A. Thiessen, E. E. Bolton et al., “PubChem substance and compound databases,” *Nucleic Acids Research*, vol. 44, no. D1, pp. D1202–D1213, 2016.
- [26] Y. H. Li, C. Y. Yu, X. X. Li et al., “Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics,” *Nucleic Acids Research*, vol. 46, no. D1, pp. D1121–D1127, 2018.
- [27] D. Sulakhe, S. Balasubramanian, B. Xie et al., “Lynx web services for annotations and systems analysis of multi-gene disorders,” *Nucleic Acids Research*, vol. 42, no. D1, pp. W473–W477, 2014.
- [28] D. Szklarczyk, J. H. Morris, H. Cook et al., “The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible,” *Nucleic Acids Research*, vol. 45, no. D1, pp. D362–D368, 2017.
- [29] M. E. Smoot, K. Ono, J. Ruscheinski, P.-L. Wang, and T. Ideker, “Cytoscape 2.8: new features for data integration and network visualization,” *Bioinformatics*, vol. 27, no. 3, pp. 431–432, 2011.
- [30] H. de Jong, J. Geiselmann, C. Hernandez, and M. Page, “Genetic network analyzer: qualitative simulation of genetic regulatory networks,” *Bioinformatics*, vol. 19, no. 3, pp. 336–344, 2003.
- [31] X. Liu, S. Ouyang, B. Yu et al., “PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach,” *Nucleic Acids Research*, vol. 38, no. 2, pp. W609–W614, 2010.
- [32] J. Li, B. Cao, X. Liu et al., “Berberine suppresses androgen receptor signaling in prostate cancer,” *Molecular Cancer Therapeutics*, vol. 10, no. 8, pp. 1346–1356, 2011.
- [33] M. Lukitasari, D. A. Nugroho, and N. Widodo, “Chlorogenic acid: the conceivable chemosensitizer leading to cancer growth suppression,” *Journal of Evidence-Based Integrative Medicine*, vol. 23, Article ID 2515690X1878962, 2018.
- [34] J. I. Kang, J.-Y. Hong, J. S. Choi, and S. K. Lee, “Columbianadin inhibits cell proliferation by inducing apoptosis and necroptosis in HCT116 colon cancer cells,” *Biomolecules & Therapeutics*, vol. 24, no. 3, pp. 320–327, 2016.
- [35] K. N. Chidambara Murthy, G. K. Jayaprakasha, and B. S. Patil, “Obacunone and obacunone glucoside inhibit human colon cancer (SW480) cells by the induction of apoptosis,” *Food and Chemical Toxicology*, vol. 49, no. 7, pp. 1616–1625, 2011.
- [36] R. Boly, T. Gras, T. Lamkami et al., “Quercetin inhibits a large panel of kinases implicated in cancer cell biology,” *International Journal of Oncology*, vol. 38, no. 3, pp. 833–842, 2011.
- [37] M. J. Ryu and H. S. Chung, “[10]-Gingerol induces mitochondrial apoptosis through activation of MAPK pathway in HCT116 human colon cancer cells,” *In Vitro Cellular & Developmental Biology—Animal*, vol. 51, no. 1, pp. 92–101, 2015.
- [38] M. H. Shoja, N. D. Reddy, P. G. Nayak, K. K. Srinivasan, and C. M. Rao, “Glycosmis pentaphylla (Retz.) DC arrests cell cycle and induces apoptosis via caspase-3/7 activation in breast cancer cells,” *Journal of Ethnopharmacology*, vol. 168, pp. 50–60, 2015.
- [39] Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi, “RAS oncogenes: weaving a tumorigenic web,” *Nature Reviews Cancer*, vol. 11, no. 11, pp. 761–774, 2011.
- [40] B. C. Netzel and S. K. Grebe, “Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer,” *Clinica Chimica Acta*, vol. 425, pp. 1–2, 2013.
- [41] J. Downward, “Targeting RAS signalling pathways in cancer therapy,” *Nature Reviews Cancer*, vol. 3, no. 1, pp. 11–22, 2003.
- [42] H. J. Andreyev, A. R. Norman, D. Cunningham et al., “Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study,” *British Journal of Cancer*, vol. 85, no. 5, pp. 692–696, 2001.
- [43] W. S. Samowitz, K. Curtin, D. Schaffer et al., “Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study,” *Cancer Epidemiol Biomarkers Prev*, vol. 9, no. 11, pp. 1193–1197, 2000.
- [44] J.-K. Lin, S.-C. Chang, H.-S. Wang et al., “Distinctive clinicopathological features of Ki-ras mutated colorectal cancers,” *Journal of Surgical Oncology*, vol. 94, no. 3, pp. 234–241, 2006.
- [45] Z. Li, Y. Chen, D. Wang, G. Wang, L. He, and J. Suo, “Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients,” *Journal of International Medical Research*, vol. 40, no. 4, pp. 1589–1598, 2012.
- [46] Y.-Y. Chang, P.-C. Lin, H.-H. Lin et al., “Mutation spectra of RAS gene family in colorectal cancer,” *The American Journal of Surgery*, vol. 212, no. 3, pp. 537–544, 2016.
- [47] M. Raponi, H. Winkler, and N. C. Dracopoli, “KRAS mutations predict response to EGFR inhibitors,” *Current Opinion in Pharmacology*, vol. 8, no. 4, pp. 413–418, 2008.
- [48] J. Espada, M. Pérez-Moreno, V. M. M. Braga, P. Rodriguez-Viciano, and A. Cano, “H-Ras activation promotes cytoplasmic accumulation and phosphoinositide 3-OH kinase association of beta-catenin in epidermal keratinocytes,” *The Journal of Cell Biology*, vol. 146, no. 5, pp. 967–980, 1999.
- [49] W. Beukers, A. Hercegovac, and E. C. Zwarthoff, “HRAS mutations in bladder cancer at an early age and the possible association with the Costello syndrome,” *European Journal of Human Genetics*, vol. 22, no. 6, pp. 837–839, 2014.
- [50] S. I. Chiosea, J. R. Grandis, V. W. Lui et al., “PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma,” *BMC Cancer*, vol. 13, p. 602, 2013.

- [51] M.-L. Chong, M. Loh, B. Thakkar, B. Pang, B. Iacopetta, and R. Soong, "Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation," *International Journal of Cancer*, vol. 134, no. 5, pp. 1232–1238, 2014.
- [52] G. Cathomas, "PIK3CA in colorectal cancer," *Frontiers in Oncology*, vol. 4, p. 35, 2014.
- [53] I. H. Sahin and C. Garrett, "Aspirin, PIK3CA mutation, and colorectal-cancer survival," *New England Journal of Medicine*, vol. 368, no. 3, p. 289, 2013.
- [54] Q. Wang, Y. L. Shi, K. Zhou et al., "PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer," *Cell Death & Disease*, vol. 9, no. 7, p. 739, 2018.
- [55] T. D. Christensen, J. A. Palshof, F. O. Larsen et al., "Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemoresistant metastatic colorectal cancer," *Acta Oncologica*, vol. 57, no. 8, pp. 1057–1062, 2018.
- [56] J. Kaur and S. N. Sanyal, "PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac," *Tumor Biology*, vol. 31, no. 6, pp. 623–631, 2010.
- [57] X. Luo, C. Z. Wang, J. Chen et al., "Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells," *International Journal of Oncology*, vol. 32, no. 5, pp. 975–983, 2008.
- [58] H. Wang, D. Taverna, D. O. Stram et al., "Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk," *Cancer Epidemiology Biomarkers & Prevention*, vol. 22, no. 11, pp. 2094–2101, 2013.
- [59] T. Wang, H. Xu, X. Liu, S. Chen, Y. Zhou, and X. Zhang, "Identification of key genes in colorectal cancer regulated by miR-34a," *Medical Science Monitor*, vol. 23, pp. 5735–5743, 2017.
- [60] C. M. Moon, J.-H. Kwon, J. S. Kim et al., "Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPAR γ in colorectal cancer," *International Journal of Cancer*, vol. 134, no. 3, pp. 519–529, 2014.
- [61] D. Gu, S. Li, M. Du et al., "A genetic variant located in the miR-532-5p-binding site of TGFBR1 is associated with the colorectal cancer risk," *Journal of Gastroenterology*, vol. 54, no. 2, pp. 141–148, 2019.
- [62] R. Zhou, Y. Huang, B. Cheng, Y. Wang, and B. Xiong, "TGFBR1 * 6A is a potential modifier of migration and invasion in colorectal cancer cells," *Oncology Letters*, vol. 15, no. 3, pp. 3971–3976, 2018.
- [63] H. He, X. Zhao, Z. Zhu et al., "MicroRNA-3191 promotes migration and invasion by downregulating TGFBR2 in colorectal cancer," *Journal of Biochemical and Molecular Toxicology*, 2019.
- [64] P. Ullmann, F. Rodriguez, M. Schmitz et al., "The miR-371~373 cluster represses colon cancer initiation and metastatic colonization by inhibiting the TGFBR2/ID1 signaling axis," *Cancer Research*, vol. 78, no. 14, pp. 3793–3808, 2018.
- [65] H. Ammon and M. Wahl, "Pharmacology of *Curcuma longa*," *Planta Medica*, vol. 57, no. 01, pp. 1–7, 1991.
- [66] H. Matsuda, A. Ishikado, N. Nishida et al., "Hepatoprotective, superoxide scavenging, and antioxidative activities of aromatic constituents from the bark of *Betula platyphylla* var. *japonica*," *Bioorganic & Medicinal Chemistry Letters*, vol. 8, no. 21, pp. 2939–2944, 1998.
- [67] J. Li, F. Zhao, M. Z. Li, L. X. Chen, and F. Qiu, "Diarylheptanoids from the rhizomes of *Curcuma kwangsiensis*," *Journal of Natural Products*, vol. 73, no. 10, pp. 1667–1671, 2010.
- [68] K. H. Kim, E. Moon, H. K. Kim et al., "Phenolic constituents from the rhizomes of *Acorus gramineus* and their biological evaluation on antitumor and anti-inflammatory activities," *Bioorganic & Medicinal Chemistry Letters*, vol. 22, no. 19, pp. 6155–6159, 2012.
- [69] J. D. Wansi, M. A. Mesaik, D. D. Chiozem et al., "Oxidative burst inhibitory and cytotoxic indoloquinazoline and furoquinoline alkaloids from *Oricia suaveolens*," *Journal of Natural Products*, vol. 71, no. 11, pp. 1942–1945, 2008.
- [70] I. R. Turnbull and M. Colonna, "Activating and inhibitory functions of DAP12," *Nature Reviews Immunology*, vol. 7, no. 2, pp. 155–161, 2007.
- [71] P. Parcesepe, G. Giordano, C. Laudanna, A. Febbraro, and M. Pancione, "Cancer-associated immune resistance and evasion of immune surveillance in colorectal cancer," *Gastroenterol Res Pract*, vol. 2016, Article ID 6261721, 8 pages, 2016.
- [72] R. M. Manzat Saplacan, L. Balacescu, C. Gherman et al., "The role of PDGFs and PDGFRs in colorectal cancer," *Mediators of Inflammation*, vol. 2017, Article ID 4708076, 9 pages, 2017.
- [73] T. J. Price, M. Tang, P. Gibbs et al., "Targeted therapy for metastatic colorectal cancer," *Expert Review of Anticancer Therapy*, vol. 18, no. 10, pp. 991–1006, 2013.
- [74] I. E. Demir, E. Tieftrunk, S. Schorn, H. Friess, and G. O. Ceyhan, "Nerve growth factor & TrkA as novel therapeutic targets in cancer," *Biochimica et Biophysica Acta (BBA)—Reviews on Cancer*, vol. 1866, no. 1, pp. 37–50, 2016.
- [75] C.-Z. Wang, X. Luo, B. Zhang et al., "Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells," *Cancer Chemotherapy and Pharmacology*, vol. 60, no. 1, pp. 69–79, 2007.
- [76] M. Wiesweg, H. Reis, T. Köster et al., "Phosphorylation of p70 ribosomal protein S6 kinase β -1 is an independent prognostic parameter in metastatic colorectal cancer," *Clinical Colorectal Cancer*, vol. 17, no. 2, pp. e331–e352, 2018.
- [77] M. Verstraete, A. Debucquoy, A. Gonnissen et al., "In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer," *BMC Cancer*, vol. 15, p. 946, 2015.
- [78] Z. N. Erdem, S. Schwarz, D. Drev et al., "Irinotecan upregulates fibroblast growth factor receptor 3 expression in colorectal cancer cells, which mitigates irinotecan-induced apoptosis," *Translational Oncology*, vol. 10, no. 3, pp. 332–339, 2017.
- [79] D. Jiang, J. Li, J. Li et al., "Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells," *International Journal of Oncology*, vol. 51, no. 5, pp. 1611–1620, 2017.



Hindawi

Submit your manuscripts at
www.hindawi.com

